This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Renal disease				
Renal damage	Colony stimulating factor 1 receptor (CSF1R; C-FMS; CD115); macrophage colony-stimulating factor 1 (CSF1; M-CSF)	<p>Studies in mice suggest that increasing CSF1 could be useful for treating acute renal injury. In a mouse model of acute ischemic renal injury, exogenous CSF1 significantly improved renal function compared with saline ($p < 0.05$). Compared with controls, CSF1-treated mice had less kidney fibrosis. Conversely, an antibody to CSF1R increased fibrosis and renal impairment compared with a control antibody. Next steps could include identifying CSF1-associated factors that reduce fibrosis.</p> <p>Cytosan cyclophosphamide, an alkylating agent from Bristol-Myers Squibb Co., is marketed to treat renal damage.</p> <p>At least ten other companies have compounds in Phase II or earlier to treat renal damage.</p> <p>SciBX 2(28); doi:10.1038/scibx.2009.1119 Published online July 23, 2009</p>	Patent and licensing status unavailable	<p>Menke, J. <i>et al.</i> <i>J. Clin. Invest.</i>; published online July 1, 2009; doi:10.1172/JCI39087</p> <p>Contact: Vicki Rubin Kelley, Brigham and Women's Hospital, Boston, Mass. e-mail: vkelly@rics.bwh.harvard.edu</p>